课题基金 / 基金详情

SB210396 IN TREATMENT OF RHEUMATOID ARTHRITIS

SB210396 IN TREATMENT OF RHEUMATOID ARTHRITIS
SB210396 治疗类风湿关节炎
批准号:
6279126
负责人:
MICHAEL H WEISMAN
金额:
$1.43万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-12-01 至 1998-11-30

项目摘要

项目成果

MICHAEL H WEISMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To compare safety and efficacy of 3 IV doses of SB-210396 with placebo in producing clinical improvement in patients with stable but active rheumatoid arthritis, to determine the time to onset of clinical effect and duration of effect after cessation of treatment, and to determine if patients treated but who do not respond have an improved response following institution of conventional DMARD therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RECOMBINANT HUMAN INTERLEUKIN ELEVEN IN RHEUMATOID ARTHRITIS
STUDY OF ORAL CCII IN TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS
INDUCTION COURSE & MAINTENANCE CYCLE OF AG4263 IN RHEUMATOID ARTHRITIS
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
海外基金